W. R. BERKLEY CORP (WRB): what the price requires

At today's price, W. R. BERKLEY CORP (WRB) is priced for 16.4% return on equity. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/WRB

Headline

FieldValue
TickerWRB
CompanyW. R. BERKLEY CORP
Current price$73.71/sh
CompositionInsurance 88% / Reinsurance & Monoline Excess 12%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisfinancials
Return on equity needed16.4%
Return on equity now18.3%
ROE gap-1.9pp
Price-to-book2.82x

Solve inputs: computed at a 8.4% cost of equity with 4% terminal growth over a 5-year stage, on common book equity (FY2026); each 1pp of cost of equity moves the implied ROE ~2.8pp.

How unusual the bet is: within-range

ReferenceValue
vs own history+0.92σ
cohort percentile (of 80 peers)75
sustained it ~10 years at this level56%
implied end-window share0%

Valuation X-Ray

The price is supported by earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.43x3expensive
Earnings0.96x2justifies
Relative0.61x3justifies
Growth1.16x1expensive

Families that justify the price: Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 5.5%); the inversion above states its own rate.

Per-Model Detail (n=9)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth——no—
Bank Fair Value (P/TBV)—$81.280.91xyesTBVPS $24.20 × 3.36x (ROE (TTM) 19.3% / CoE 9.3%, g=5.0% (sustainable: 65% retention × ROE, 5% cap; not the terminal-growth assumption))
Relative ValuationRelative$55.881.32xyesP/E 11x (static sector reference · 2026-04), scenarios: 9.2x / 11.0x / 12.8x (bear / base = reference held flat / bull), EV/EBITDA 10x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$51.401.43xyesBV/sh $24.67, ROE (TTM) 19.3%, ke 9.3%
Two-Stage Excess ReturnAsset$73.351.00xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$63.281.16xyesRev $14.9B, growth 7% (input: historical growth; tapered), Terminal P/S: 1.6x / 2.0x / 2.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$120.690.61xyesEPS $4.72, growth 26% (input: historical EPS growth), PEG=0.61 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings——no—
Residual IncomeAsset——no—
Graham NumberAsset$51.191.44xyes√(22.5 × EPS $4.72 × BVPS $24.67) — Graham's conservative floor
EV/EBITDA RelativeRelative——no—
FCF YieldEarnings——no—
SBC-Adj FCF YieldEarnings——no—
Ben Graham FormulaEarnings$152.300.48xyesEPS $4.72 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset——no—
P/Sales SectorRelative——no—
PEG Fair ValueRelative$177.000.42xyesEPS $4.72 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$51.031.44xyesEPS $4.72 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Share count CAGR (buyback)-1.5%

Deposit/float-funded balance sheet: debt is funding, not corporate leverage, and GAAP operating cash flow follows loan flows. Net-debt, interest-coverage, and cash-burn lenses do not apply. The solvency frame for a financial is regulatory capital and payout capacity (CET1, stress buffer, dividends plus buybacks against earnings).

Bullet Takeaways

Bull Case

W. R. Berkley's structural advantage is underwriting discipline, and the return data shows it is real, not rhetorical. A property-casualty insurer's moat is not a brand or a network; it is the ability to price risk better than competitors and to walk away from business that is mispriced. Berkley does exactly that. In Q1 2026 it posted a consolidated combined ratio of 90.7 percent, meaning it kept roughly 9 cents of underwriting profit on every premium dollar before any investment income, with the reinsurance segment at 78.6 percent. A return on equity of 21.2 percent, more than double the cost of equity, is the signature of a franchise that earns far above its required return year after year. That is the structural advantage: a decentralized network of specialty units, each run by underwriters close to their niche, that compounds book value at high rates.

The profitability is broad-based and growing. Net income reached a record 515.2 million dollars, up 23.4 percent, and operating income hit a record 514.3 million dollars, while net investment income grew 12.2 percent to a record 404.3 million dollars as Berkley reinvested its bond portfolio at higher yields. The dual engine of an insurer, underwriting profit plus investment income on the float, is firing on both cylinders: disciplined underwriting holds the combined ratio below 91, and the rate environment lets the investment portfolio earn more on the premiums held before claims are paid.

Management's willingness to shrink where pricing is poor is the clearest proof of the moat. The reinsurance segment contracted in the quarter because Berkley walked away from competitive pricing rather than chase volume, while the insurance segment still grew net premiums written 3.2 percent, led by professional lines and international. A company that will sacrifice top-line growth to protect underwriting margin is one whose culture is built around return on capital, not premium for its own sake. The engine reads the stock as supported by earnings-power and relative-multiple value, a value-and-asset name rather than a pure growth bet, with a bank-style fair value on tangible book around 81 dollars above the price. The bull case is a best-in-class compounder with a 21 percent ROE, bought at a sensible multiple of book.

Bear Case

The competitive disruption facing Berkley is the insurance cycle itself, and the competitors driving it are both established carriers and a wave of new capital. Property-casualty pricing moves in cycles, and after several years of hardening rates the market is softening: new capital is entering the reinsurance space and established carriers are seeking to grow market share, which leads to slower rate increases or outright softening in certain lines. Berkley's own response, shrinking its reinsurance book because it would not match competitive pricing, is admirable discipline but also a direct symptom of the problem. When rivals are willing to write business at prices Berkley considers inadequate, Berkley either cedes share or compromises its underwriting standard, and a softening cycle means this pressure broadens from reinsurance into the commercial-insurance lines that drive most of its premium.

The second concern is reserve adequacy, the perennial soft spot of a P&C insurer. The company has recorded meaningful adverse development on prior-year reserves, and its filing points readers to the reconciliation of reserve estimates and the changes for claims occurring in prior years (FY2025 10-K, accession 0000011544-26-000005). Adverse development means losses on old policies came in worse than reserved, and in a softening market where loss-cost inflation can outrun rate increases, the risk is that today's healthy combined ratio is partly a function of reserve assumptions that later prove optimistic. If loss-cost trends continue above rate increases, the margin that looks comfortable now can compress quickly, and reserve strengthening would hit earnings directly.

Valuation leaves modest room for these risks. The stock trades at a full multiple relative to peers given where the industry sits in its cycle, and several analysts have trimmed price targets on concerns that 2026 and 2027 consensus earnings may be too high. The growth-DCF frame already reads the stock as expensive, and the bank-style and excess-return frames, while supportive, assume the high ROE persists. A 21 percent ROE and a sub-91 combined ratio are excellent, but they are near the top of what this business produces, and buying a cyclical at peak profitability with softening pricing and unresolved reserve questions is the classic way to overpay for quality. The bear case is not that Berkley is a bad company; it is that the cycle is turning against even the best underwriter, and the price assumes the good times continue.

Valuation

W. R. Berkley is a financial, so its valuation is best read through return on equity and book value rather than operating margins, and the X-ray reflects that. The bank-style fair value, which capitalizes tangible book at a multiple justified by the spread between ROE and cost of equity, lands around 81 dollars, above the 67-dollar price, on a tangible book value per share of 24.20 dollars and a 19.3 percent trailing ROE. The asset-based excess-return reads bracket the price, with the simple version near 51 dollars and the two-stage version near 73 dollars. The relative-valuation frame at a sector P/E near 11 times lands around 56 dollars, and the Peter Lynch read near the price. The growth-DCF read is the dissent, landing near 31 dollars, because applying a revenue-growth-and-fade model to an insurer understates the value created by underwriting and investment income.

The engine characterizes the stock as supported by earnings-power and relative-multiple value while growth-DCF says expensive, which is the right read: this is a value-and-asset name whose worth lives in its ability to compound book value at a high ROE, not in revenue growth. The honest anchor is the relationship between the 19-to-21 percent ROE and the roughly 9 percent cost of equity. As long as that spread persists, Berkley deserves to trade well above book, and the bank-style read near 81 dollars captures that.

The synthesis is that Berkley is a high-quality compounder priced at a fair-to-full multiple, and the key judgment is whether the current ROE is sustainable. At a sub-91 combined ratio and record investment income, the profitability is near a cyclical high, so paying a premium-to-peer multiple embeds an assumption that the soft market does not erode the underwriting margin and that reserves prove adequate. The book-value floor and the high through-cycle ROE limit the downside relative to a non-financial, but the upside requires the spread between ROE and cost of equity to hold as pricing softens. This is a buy-the-quality-at-a-reasonable-price name, with the caveat that the entry multiple assumes the underwriting cycle stays benign.

Catalysts

The dominant catalyst is the property-casualty pricing cycle. With new capital entering reinsurance and established carriers seeking share, rate increases are slowing, so the trajectory of Berkley's net premiums written and its combined ratio over coming quarters is the clearest read on whether the soft market is eroding underwriting margin. Berkley's willingness to shrink lines where pricing is inadequate, as it did in reinsurance, is the discipline to watch; continued margin protection at the cost of growth is a positive sign, while any combined-ratio deterioration would signal the cycle biting.

The second catalyst is reserve development and investment income. Adverse prior-year reserve development is the key risk metric for any P&C insurer, so each quarter's reserve commentary, and whether loss-cost inflation runs above rate increases, will determine whether the healthy combined ratio is durable. Net investment income, which hit a record on higher reinvestment yields, is a tailwind that depends on the rate environment, so the path of interest rates feeds directly into the float's earnings. Analyst sentiment is mixed, with some price-target cuts on concerns that 2026 and 2027 consensus earnings are too high, so delivery against those estimates is itself a catalyst given the full valuation.

Sources: W. R. Berkley Q1 2026 earnings jump with 21.2 percent ROE, stocktitan.net; W. R. Berkley reports first quarter 2026 results, streetinsider.com; W.R. Berkley SWOT analysis, insurance stock faces growth concerns, investing.com; W. R. Berkley record Q1 operating income, insurancejournal.com.

Peer Cohorts (Per Segment, With Filing Citations)

Insurance (reported)

Reinsurance & Monoline Excess (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive WRB report on boothcheck